蒋德科教授，复旦大学遗传学博士，美国芝加哥大学博士后，美国维克森林大学访问学者。曾任复旦大学遗传工程国家重点实验室技术组副组长，复旦大学生命科学学院遗传流行病学研究中心副主任。现任南方医科大学南方医院肝病中心教授、研究员、博士生导师，兼任广东省精准医学应用学会肝病分会常委、广东省精准医学应用学会精准免疫治疗分会常委等职务。

长期从事肝病的遗传流行病学、功能基因组学、药物基因组学与精准医学研究，致力于揭示慢性乙型肝炎和肝癌发生发展和免疫逃逸的分子机制、开发肝癌的分子靶向药物、探索肝癌的免疫治疗和细胞免疫治疗。已在《Nature Genetics》、《Nature Communications》、《Hepatology》、《Gut》、《Cancer Research》、《Clinical Gastroenterology and Hepatology》、《Alimentary Pharmacology & Therapeutics》、《Clinical Pharmacology & Therapeutics》、《Journal of Clinical Microbiology》、《Journal of Infectious Diseases》、《Liver International》等杂志上发表SCI论文90余篇，引用达3000余次，单篇引用超过350次。其中作为第一作者发表于《Nature Genetics》的研究论文被科学网评选为当年度国内“十大最受关注”的科学研究，并被中央电视台新闻联播等媒体所广泛报道。

承担国家重大科技专项（子项目负责人）、国家重点研发计划（子任务负责人）、国家自然科学基金面上项目（3项）、国家自然科学基金青年基金项目、广东省“珠江人才计划”本土创新科研团队项目（子项目负责人）、广东省自然科学基金面上项目、广东省基础与应用基础研究基金企业联合基金面上项目、南方医院“杰出青年培育计划”项目、南方医院高层次人才科研启动项目、南方医院院长基金等科研项目10余项，总经费超过1300万元。

担任《Hapaloma Research》杂志编委，《Journal of Translational Genetics and Genomics》杂志青年编委， 是美国人类遗传学会（ASHG）会员，美洲华人遗传学会（ACGA）会员。曾多次在亚太肝病研究学会（APASL）、美洲肝病研究学会（AASLD）和美国人类遗传学会（AHSG）等的年会上作特邀报告或口头报告。

获得国家自然科学奖二等奖、教育部自然科学奖一等奖、中国抗癌协会科技奖二等奖、广东省科技进步一等奖、复旦大学“复星医药奖教金”特等奖、罗氏诊断“中国医学及生命科学教育研究基金”等奖励。

肝病的遗传流行病学、功能基因组学、药物基因组学与精准医学研究。具体包括采用生物信息方法和大规模病例样本数据的统计分析，以及分子、细胞、小鼠、类器官等功能实验，全基因组筛查乙肝和肝癌的遗传易感基因，探讨宿主基因组和乙肝病毒基因组之间的交互作用，研究肝病发生发展和免疫逃逸的分子机制，鉴定乙肝现有一线药物治疗应答的生物标志物，开发新型的肝癌靶向药物和免疫治疗以及细胞免疫治疗方案等。

1.     HLA-DQB1*03:01 and risk of HBV-related HCC. Zhang T, Huang CJ, Chen HT, Huang YH, Pan MH, Lee MH, Viard M, Hildesheim A, Pfeiffer RM, Carrington M, Chen CJ, Zhu B, Lenz TL, Jiang D*, Yang HI*, Liu Z*. Hepatology. 2025. Online ahead of print.

2.     Zeng W, Zhu W, Yuan G, Chen J, Wang Z, Hou J, Jiang DK*. TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects. Cancer Immunol Immunother. 2025;74(8):257.

3.     Luo M, Liang X, Zhou B, Hou J, Jiang DK*. CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients. Antiviral Res. 2024 ;231:106005. 

4.     Luo M, Dong C, Liang X, Na R, Zhou B, Hou J, Jiang DK*. A genetic variant of CXCR4 predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients. J Clin Microbiol. 2024;62(2):e0139623.

5.     Chen J, Hou J, Na R, Zhou B, Hou J, Jiang DK*. Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients. Clin Pharmacol Ther. 2024;115(2):361-370.

6.     Xie H, Huang G, Mai H, Chen J, Na R, Jiang DK*. Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes. Cancer Med. 2024;13(15):e70081.  

7.     Hou J, Dong C, Chen J, Chen H, Na R, Zhou B, Hou J, Jiang DK*. An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients. Antiviral Res. 2023 ;220:105741. 

8.     Luo M, Zhang L, Yang C, Zhou B, Hou J, Jiang DK*. CXCL13 variant predicts pegylated-interferon α treatment response in HBeAg-positive chronic hepatitis B patients. J Med Virol. 2023; 95(7):e28963. 

9.     Lou S, Wang J, Chen J, Xie H, Chen H, Zhou B, Zhang B, Hou J, Jiang DK*. The Role of ALPK1 in Inhibiting HBV Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting PegIFNα Therapy Response. J Infect Dis. 2023. Online ahead of print.

10.     Li S, Wang J, Chen H, Hou J, Shen T, Li J, Zhou B, Zhang B, Liu H, Jiang DK*. TRIM16 E121D variant affects the risk and prognosis of hepatocellular carcinoma by modulating the Wnt/β-catenin pathway. Mol Carcinog. 2023;62(11):1686-1699.

11.     Chen J, Chen H, Mai H, Lou S, Luo M, Xie H, Zhou B, Hou J, Jiang DK*. A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. Hum Mol Genet. 2023; 32(8):1334-1347.

12.     Chen J, Lou S, Chen H, Zhou B, Sun J, Hou J, Jiang DK*. CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. J Clin Transl Hepatol. 2023; 11(2):295-303.

13.     Shen T, Ni T, Chen J, Chen H, Ma X, Cao G, Wu T, Xie H, Zhou B, Wei G, Saiyin H, Shen S, Yu P, Xiao Q, Liu H, Gao Y, Long X, Yin J, Guo Y, Wu J, Wei GH, Hou J, Jiang DK*. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression. Nat Commun. 2022; 13(1):1232.

14.     Luo M, Hou J, Mai H, Chen J, Chen H, Zhou B, Hou J, Jiang DK*. TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg-positive chronic hepatitis B Patients. Aliment Pharmacol Ther. 2022; 56(5):878-889.

15.     Luo M, Zhou B, Hou J, Jiang D*. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res. 2022; 52(4):337-351.

16.     Mai H, Xie H, Luo M, Hou J, Chen J, Hou J, Jiang DK*. Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds. Cancers (Basel). 2022; 14(3):563.

17.   Yang C, Chen H, Zhou B, Yin J, Cao G, Hou J, Jiang D*. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma. Mol Carcinog. 2022; 61(10):933-940.

18.   Mai H, Chen J, Chen H, Liu Z, Huang G, Wang J, Xiao Q, Ren W, Zhou B, Hou J, Jiang D*. Fine Mapping of the MHC Region Identifies Novel Variants Associated with HBV-Related Hepatocellular Carcinoma in Han Chinese. J Hepatocell Carcinoma. 2021; 8:951-961.

19.   Mai H, Xie H, Hou J, Chen H, Zhou B, Hou J, Jiang D*. A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis. J Hepatocell Carcinoma. 2021; 8:1055-1064. 

20.   Chen J, Mai H, Chen H, Zhou B, Hou J, Jiang DK*. Pan-Cancer Analysis Identified C1ORF112 as a Potential Biomarker for Multiple Tumor Types. Front Mol Biosci. 2021; 8:693651.

21.   Shen T, Li SF, Wang JL, Zhang T, Zhang S, Chen HT, Xiao QY, Ren WH, Liu C, Peng B, Ji XN, Yang Y, Lu PX, Chen TY, Yu L, Ji Y, Jiang DK*. TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy. Liver Int. 2020; 40(11):2834-2847. 

22.   Chen H, Sun J, Zhou B, Peng J, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK*. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther. 2020; 51(4):469-478. 

23.   Chen H, Sun J, Zhou B, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK*. Variants in STAT4 associated with cure of chronic HBV infection in HBeAg-positive patients treated with pegylated interferon-alpha. Clin Gastroenterol Hepatol. 2020; 18(1):196-204.e8. 

24.   Yang C, Mai H, Peng J, Zhou B, Hou J, Jiang D*. STAT4: an immunoregulator contributing to diverse human diseases. Int J Biol Sci. 2020; 16(9):1575-1585.

25.   Jiang D, Deng J, Dong C, Ma X, Xiao Q, Zhou B, Yang C, Wei L, Conran C, Zheng SL, Ng IO, Yu L, Xu J, Sham PC, Qi X, Hou J, Ji Y, Cao G, Li M. Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. BMC Cancer. 2020; 20(1):403. 

26.   Mai H, Zhou B, Liu L, Yang F, Conran C, Ji Y, Hou J, Jiang D*. Molecular pattern of lncRNAs in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):198.

27.   Jiang DK*, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2016; 63(4):1102-11.

28.   Jiang DK*, Ma XP, Yu H, Cao G, Ding DL, Chen H, Huang HX, Gao YZ, Wu XP, Long XD, Zhang H, Zhang Y, Gao Y, Chen TY, Ren WH, Zhang P, Shi Z, Jiang W, Wan B, Saiyin H, Yin J, Zhou YF, Zhai Y, Lu PX, Zhang H, Gu X, Tan A, Wang JB, Zuo XB, Sun LD, Liu JO, Yi Q, Mo Z, Zhou G, Liu Y, Sun J, Shugart YY, Zheng SL, Zhang XJ, 8. Xu J, Yu L. Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B. Hepatology. 2015; 62(1):118-28. 

29.   Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013; 45(1):72-5.